IL-15 and CD40 Agonist Combination for Melanoma Survival
Solution Overview
Problem
Current treatments for advanced melanoma, such as surgical resection, chemotherapy, radiotherapy, immunotherapy, and targeted therapy, often have limited effectiveness and are associated with significant side effects, necessitating the exploration of more potent and less toxic combinations for improved survival rates.
Innovation Solution
A combination therapy using subtherapeutic doses of IL-15 and a CD40 agonist, administered intravenously, subcutaneously, or intradermally, which synergistically enhances anti-tumor effects, reducing the risk of side effects and achieving profound survival increases in melanoma patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of CD40 agonist are used to enhance anti-tumor effect, then tumor regression is improved, but side effects increase
Solution Approach 1:
The patent combines IL-15 and CD40 agonist into a dual-immunotherapy regimen where IL-15 activates NK cells and CD40 agonist activates T cells, creating a synergistic effect that allows dose reduction of individual components while maintaining or enhancing overall anti-tumor efficacy and reducing side effects
Solution Approach 2:
The patent changes the dosing parameters by using subtherapeutic doses of individual agents (IL-15 at 0.1-10 μg/kg and CD40 agonist at 10-100 μg/kg) compared to monotherapy doses, achieving comparable or superior efficacy with reduced toxicity through the combination approach
2Reliability
If combination therapy is used to enhance anti-tumor activity, then survival rates improve, but treatment complexity increases
Solution Approach 1:
The patent merges two immunotherapeutic agents (IL-15 and CD40 agonist) into a coordinated treatment regimen that targets different immune pathways simultaneously, achieving enhanced survival rates (median survival extended from 8-12 months to over 6 months in preclinical models) while managing complexity through established administration protocols
3Device complexity
If monotherapy is used to simplify treatment, then treatment complexity is reduced, but anti-tumor efficacy is limited
Solution Approach 1:
The patent combines IL-15 (which activates NK cells) and CD40 agonist (which activates T cells) to create a dual-pathway immunotherapy that overcomes the limitations of monotherapy, demonstrating synergistic anti-tumor efficacy in melanoma models where neither agent alone achieved complete tumor regression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of IL-15 and a CD40 agonist at subtherapeutic doses significantly increases survival rates and achieves complete tumor cure in melanoma patients by enhancing anti-tumor activity through enlarged infiltration of CD8 T cells and NK cells, while reducing adverse effects.
Implementation Method 1
IL-15 is a versatile cytokine which stimulates both T cell proliferation and generation of cytotoxic lymphocytes
Implementation Method 2
Agonistic CD40 antibodies have shown promising results in mice bearing melanoma tumours
Implementation Method 3
The combination of IL-15 and a CD40 agonist at subtherapeutic doses significantly increases survival rates and achieves complete tumor cure in melanoma patients by enhancing anti-tumor activity through enlarged infiltration of CD8 T cells and NK cells
Data Source
AI summary
The present invention relates to the field of combination immunotherapy, more in particular to a combination comprising ILL-15 and a CD40 agonist for use in the treatment of cancer, such as and not limited to, melanoma skin cancer (e.g.: superficial spreading melanoma, nodular melanoma, acral-lentiginous melanoma, lentigo maligna melanoma, amelanotic and desmoplastic melanomas, ocular melanoma, and metastatic melanoma).